Allergan delays drug that would rival Regeneron’s Eylea
(Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea,...
Home > Reviews
All Stories
Allergan delays drug that would rival Regeneron’s Eylea
(Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea,...
Merck, Pfizer to jointly develop diabetes drug
(Reuters) - Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other...
Merck, Pfizer to jointly develop diabetes drug
(Reuters) - Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other...
Merck veteran named R&D chief, after drug setbacks
(Reuters) - Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past...
Merck veteran named R&D chief, after drug setbacks
(Reuters) - Merck & Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past...
Jury awards woman $7.76 million in damages for J&J mesh
(Reuters) - A New Jersey jury Thursday ordered Johnson & Johnson and a subsidiary to pay $7.76 million in punitive damages to a South Dakota nurse who claimed she was...
Jury awards woman $7.76 million in damages for J&J mesh
(Reuters) - A New Jersey jury Thursday ordered Johnson & Johnson and a subsidiary to pay $7.76 million in punitive damages to a South Dakota nurse who claimed she was...
Insight: Cancer drugs proving worth earlier in testing
NEW YORK (Reuters) - Michael Weitz was out of options. The Californian had endured chemotherapy, radiation and surgery but his lung cancer still spread to his bones and brain. With...
Kellogg recalls some Special K cereal, citing glass fragments
NEW YORK (Reuters) - Kellogg Co said 36,000 packages of its Special K Red Berries cereal could contain dangerous glass fragments and have been pulled from the market, the latest...